Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Jianfeng Zhou
- Target Recruit Count
- 55
- Registration Number
- NCT05575973
- Locations
- 🇨🇳
Department of Hematology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Conditions
- Neuromyelitis Optica Spectrum Disorder
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 46
- Registration Number
- NCT05551598
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma
- Conditions
- Relapsed and Refractory Peripheral T-cell Lymphoma
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 78
- Registration Number
- NCT05527275
- Locations
- 🇨🇳
Department of Medical Oncology,Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Hui Zeng
- Target Recruit Count
- 70
- Registration Number
- NCT05522192
- Locations
- 🇨🇳
First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 45
- Registration Number
- NCT05495100
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Zhejiang, China
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT05345938
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT05344742
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Ayman H Qasrawi
- Registration Number
- NCT05330377
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
- Conditions
- Pediatric AMLLeukemia, Monocytic, Acute
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-07-27
- Target Recruit Count
- 43
- Registration Number
- NCT05313958
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.